🚀 VC round data is live in beta, check it out!
- Public Comps
- Lumexa Imaging
Lumexa Imaging Valuation Multiples
Discover revenue and EBITDA valuation multiples for Lumexa Imaging and similar public comparables like Guangzhou Wondfo Biotech, Daan Gene, Ramsay Santé, Vimian Group and more.
Lumexa Imaging Overview
About Lumexa Imaging
Lumexa Imaging Holdings Inc is a provider of diagnostic imaging services. The company offers a broad range of imaging modalities including MRIs, CT scans, PET scans, X-rays, ultrasounds, and mammography. Its products and operations are managed and reported in two operating segments: Outpatient Imaging Centers (Outpatient) and Professional Services (Professional). The professional services segment generates revenue from interpreting imaging studies conducted by other parties, mainly hospital imaging departments. The majority of revenue is generated from the Outpatient segment, which generates revenue by performing imaging studies and providing radiologists’ interpretations of those studies.
Founded
2025
HQ

Employees
5.0K
Website
Financials (LTM)
EV
$3B
Lumexa Imaging Financials
Lumexa Imaging reported last 12-month revenue of $1B and EBITDA of $232M.
In the same LTM period, Lumexa Imaging generated $165M in gross profit, $232M in EBITDA, and had net loss of ($19M).
Lumexa Imaging P&L
In the most recent fiscal year, Lumexa Imaging reported revenue of $949M and EBITDA of $114M.
Lumexa Imaging expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1B | XXX | $949M | XXX | XXX | XXX |
| Gross Profit | $165M | XXX | $96M | XXX | XXX | XXX |
| Gross Margin | 16% | XXX | 10% | XXX | XXX | XXX |
| EBITDA | $232M | XXX | $114M | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 12% | XXX | XXX | XXX |
| EBIT Margin | 11% | XXX | (2%) | XXX | XXX | XXX |
| Net Profit | ($19M) | XXX | ($94M) | XXX | XXX | XXX |
| Net Margin | (2%) | XXX | (10%) | XXX | XXX | XXX |
| Net Debt | — | — | $1B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Lumexa Imaging Stock Performance
Lumexa Imaging has current market cap of $1B, and enterprise value of $3B.
Lumexa Imaging's stock price is $14.13.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $1B | 0.0% | XXX | XXX | XXX | $-1.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialLumexa Imaging Valuation Multiples
Lumexa Imaging trades at 2.6x EV/Revenue multiple, and 11.4x EV/EBITDA.
Lumexa Imaging Financial Valuation Multiples
As of March 29, 2026, Lumexa Imaging has market cap of $1B and EV of $3B.
Equity research analysts estimate Lumexa Imaging's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Lumexa Imaging has a P/E ratio of (70.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | 2.6x | XXX | 2.8x | XXX | XXX | XXX |
| EV/EBITDA | 11.4x | XXX | 23.2x | XXX | XXX | XXX |
| EV/EBIT | 22.6x | XXX | (162.6x) | XXX | XXX | XXX |
| EV/Gross Profit | 16.1x | XXX | 27.5x | XXX | XXX | XXX |
| P/E | (70.4x) | XXX | (14.2x) | XXX | XXX | XXX |
| EV/FCF | 128.5x | XXX | 204.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Lumexa Imaging Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Lumexa Imaging Margins & Growth Rates
Lumexa Imaging's revenue in the last 12 month grew by 5%.
Lumexa Imaging's revenue per employee in the last FY averaged $0.2M.
Lumexa Imaging's rule of 40 is 27% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Lumexa Imaging's rule of X is 34% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Lumexa Imaging Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | 102% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 27% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 34% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 5% | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 12% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Lumexa Imaging Public Comps
See public comps and valuation multiples for other Medical Imaging & Diagnostics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Guangzhou Wondfo Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Daan Gene | XXX | XXX | XXX | XXX | XXX | XXX |
| Ramsay Santé | XXX | XXX | XXX | XXX | XXX | XXX |
| Vimian Group | XXX | XXX | XXX | XXX | XXX | XXX |
| NeoGenomics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lumexa Imaging M&A Activity
Lumexa Imaging acquired XXX companies to date.
Last acquisition by Lumexa Imaging was on XXXXXXXX, XXXXX. Lumexa Imaging acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Lumexa Imaging
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialLumexa Imaging Investment Activity
Lumexa Imaging invested in XXX companies to date.
Lumexa Imaging made its latest investment on XXXXXXXX, XXXXX. Lumexa Imaging invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Lumexa Imaging
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Lumexa Imaging
| When was Lumexa Imaging founded? | Lumexa Imaging was founded in 2025. |
| Where is Lumexa Imaging headquartered? | Lumexa Imaging is headquartered in United States. |
| How many employees does Lumexa Imaging have? | As of today, Lumexa Imaging has over 5K employees. |
| Is Lumexa Imaging publicly listed? | Yes, Lumexa Imaging is a public company listed on Nasdaq. |
| What is the stock symbol of Lumexa Imaging? | Lumexa Imaging trades under LMRI ticker. |
| When did Lumexa Imaging go public? | Lumexa Imaging went public in 2025. |
| Who are competitors of Lumexa Imaging? | Lumexa Imaging main competitors are Guangzhou Wondfo Biotech, Daan Gene, Ramsay Santé, Vimian Group. |
| What is the current market cap of Lumexa Imaging? | Lumexa Imaging's current market cap is $1B. |
| What is the current revenue of Lumexa Imaging? | Lumexa Imaging's last 12 months revenue is $1B. |
| What is the current revenue growth of Lumexa Imaging? | Lumexa Imaging revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Lumexa Imaging? | Current revenue multiple of Lumexa Imaging is 2.6x. |
| Is Lumexa Imaging profitable? | Yes, Lumexa Imaging is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Lumexa Imaging? | Lumexa Imaging's last 12 months EBITDA is $232M. |
| What is Lumexa Imaging's EBITDA margin? | Lumexa Imaging's last 12 months EBITDA margin is 22%. |
| What is the current EV/EBITDA multiple of Lumexa Imaging? | Current EBITDA multiple of Lumexa Imaging is 11.4x. |
| What is the current FCF of Lumexa Imaging? | Lumexa Imaging's last 12 months FCF is $21M. |
| What is Lumexa Imaging's FCF margin? | Lumexa Imaging's last 12 months FCF margin is 2%. |
| What is the current EV/FCF multiple of Lumexa Imaging? | Current FCF multiple of Lumexa Imaging is 128.5x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.